Bill Gross warns on gold momentum as regional bank stocks tumble
Oric Pharmaceuticals Inc. has reached a new 52-week high, with its stock price climbing to 14.89 USD. This milestone marks a significant achievement for the $1.4B market cap company, reflecting a robust 51.84% increase over the past year. InvestingPro analysis indicates the stock is trading in overbought territory, with analyst price targets ranging up to $25. The surge in stock price underscores positive market sentiment and investor confidence in Oric Pharmaceuticals’ business prospects, with the stock showing impressive returns of over 213% in the past six months. This upward trajectory comes amid a broader rally in the biotech sector, as investors remain optimistic about the company’s pipeline and potential for future growth. InvestingPro subscribers have access to 12 additional insights about ORIC’s momentum and financial health.
In other recent news, ORIC Pharmaceuticals has received multiple positive evaluations from research firms, highlighting the company’s potential in cancer drug development. Cantor Fitzgerald reiterated an Overweight rating, emphasizing that ORIC remains significantly undervalued, particularly with its oral PRC2 inhibitor, ORIC-944, which is under development for prostate cancer. Guggenheim initiated coverage with a Buy rating and set a price target of $18.00, citing the promising prospects of ORIC-944 as a treatment for metastatic castration-resistant prostate cancer. Additionally, Jefferies raised its price target to $23.00, maintaining a Buy rating, following ORIC’s strategic focus on its ’944 mCRPC and ’114 NSCLC programs, with pivotal trials expected in 2026.
Moreover, Ladenburg Thalmann also initiated coverage with a Buy rating and a $15.00 price target, noting the potential of ORIC-944 as a fast-follower to Pfizer’s mevrometostat in treating AR-experienced mCRPC. In a strategic move, ORIC Pharmaceuticals appointed Kevin Brodbeck as Chief Technical Officer, a new role that aligns with the company’s preparation for potential Phase 3 trials of its cancer treatment candidates in 2026. These developments reflect a strong focus on advancing ORIC’s oncology pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.